Eye Disease Market Primed for Shake-up: Roche touts study data of experimental Antibody Faricimab
ZURICH: Swiss drugmaker Roche has touted data for a new drug against a blindness-causing eye disease that hits millions of older people, the latest sign this multi-billion-dollar market is primed for disruption.
Roche's experimental faricimab, a bispecific antibody, showed potential for extended durability in use against the disease neovascular age-related macular degeneration, it said in a statement.
Read Also: U.S. FDA panel backs Celltrion copycat of Roche blood cancer drug
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd